← All stories
● Covered by 1 source · 2 reportsMedium impact1 neutral1 positive

Engineered Adenovirus Halts Pancreatic Cancer Growth in Three Patients in Early Trial

🔄 Updated 8h ago — new reporting from Hacker News Front Page
New to BrevFeed? We gather this story from every outlet covering it into one summary — ranked by real-world impact, not just the latest headline — so you never miss what matters. What is BrevFeed? →

Key points

  • Engineered adenovirus halted pancreatic cancer growth in three patients.
  • Patients received one-tenth of the planned dose for safety testing.
  • Tumors have not grown further since treatment; patients are alive.
  • Pancreatic cancer is difficult to treat due to late diagnosis and tumor characteristics.
  • The new drug is daraxonrasib.
  • The drug is a KRAS inhibitor.
  • The trial involved 61 patients with advanced pancreatic cancer.
  • 8% of patients had undetectable cancer.
  • 90% of participants stopped tumor growth.
  • Half of all pancreatic cancer patients die within three months.
  • Only 3% of patients survive five years when the disease spreads.
  • Patients were followed for 1.5 years on average.

Early Clinical Trial Results

A clinical trial in the US has shown that a genetically engineered adenovirus stopped the progression of pancreatic cancer in three patients. These patients, who had localized tumors, received a small dose of the virus and have since maintained stable disease, with no further tumor growth observed up to a year post-treatment. The results were presented at the annual meeting of the American Society of Gene and Cell Therapy.

Mechanism of Action

The virus is an adenovirus modified to replicate exclusively within tumor cells, sparing healthy tissue. Its replication is activated by a specific enzyme found in cancer cells. This targeted approach aims to overcome the challenges of treating pancreatic cancer, such as the dense tumor exteriors that block chemotherapy and the ability of tumors to evade the immune system.

Challenges of Pancreatic Cancer

Pancreatic cancer is considered one of the deadliest forms of cancer, primarily because symptoms often appear late, by which time the cancer has typically spread and is inoperable. Additionally, pancreatic tumors are characterized by tough, fibrous exteriors that impede the delivery of chemotherapy drugs and can hide from the immune system, rendering immunotherapies ineffective.

Future Steps and Expert Perspective

While the initial results are encouraging, researchers emphasize the need for further evaluation in larger trials. The next phase of the trial will involve administering higher doses to an additional 15 patients to determine the optimal dosage. An expert noted that while this is an interesting early signal, it is important to maintain perspective, as many promising early findings in oncology do not translate to late-stage success. The current trial also lacks a control group, making it difficult to definitively compare its efficacy against other treatments or no treatment.

Updates

🕒 2026-11-21 · new reporting from Hacker News Front Page
  • The new drug is daraxonrasib.
  • The drug is a KRAS inhibitor.
  • The trial involved 61 patients with advanced pancreatic cancer.
  • 8% of patients had undetectable cancer.
  • 90% of participants stopped tumor growth.
  • Half of all pancreatic cancer patients die within three months.
  • Only 3% of patients survive five years when the disease spreads.
  • Patients were followed for 1.5 years on average.

✨ This summary was generated by AI from the outlets' reporting listed below. It is not independently verified and may contain errors — check the original sources. How BrevFeed works →

The daily brief

One email each morning: the day's tech stories, clustered across outlets and summarized. No account needed.

One email a day. Unsubscribe in one click, any time.

Today's brief

Spend a few minutes, get the whole day. Every topic's top stories in one hands-free rundown — listen, watch, or read the transcript.

~4 min · 3 stories · Nov 21

▶ Play today's brief Listen on Spotify

New every morning, and the back catalogue is archived by date.

How outlets covered it

A new drug, daraxonrasib, has shown promising results in a trial for advanced pancreatic cancer, causing tumors to become undetectable in 8% of patients and stopping tumor growth in 90% of participants. This KRAS inhibitor treatment significantly improved survival rates compared to chemotherapy, offering a potential breakthrough for a cancer with a very low survival rate.

An adenovirus, genetically engineered to replicate only in tumor cells, stopped pancreatic cancer growth in three patients during an early-stage clinical trial. The patients, who received a low dose of the virus, have stable disease and no further tumor growth a year after treatment. This initial finding suggests a potential new approach for treating pancreatic cancer, which is known for its resistance to conventional therapies.